Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 38
Filtrar
Más filtros

Banco de datos
País/Región como asunto
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Rheumatol Int ; 37(7): 1203-1206, 2017 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-28447208

RESUMEN

Antisynthetase syndrome is a heterogeneous idiopathic inflammatory myopathy. Anti-Jo1 is the most common antibody found in this condition. Dermatomyositis is known to be associated with malignancy, but the association between antisynthetase syndrome and malignancy is not clearly established. We report a case of an association of squamous cell carcinoma of the lung and anti-Jo1 antisynthetase syndrome. A 67-year-old man presented with polyarthritis, muscle weakness of the pelvic girdle, "mechanic's hands," and weight loss. A diagnosis of antisynthetase syndrome was considered based on the clinical features and the presence of anti-Jo1 antibodies. Positron emission tomography was performed because of weight loss and revealed a pulmonary hypermetabolic lesion. Histological findings revealed squamous cell carcinoma. The patient underwent lobectomy and is currently free of symptoms with regular monitoring. This unusual presentation of squamous cell carcinoma of the lung illustrates the need of a systematic approach to the diagnosis of antisynthetase syndrome. Positron emission tomography can be a useful imaging modality in the diagnosis of paraneoplastic syndromes associated with antisynthetase syndrome especially in the presence of warning signs/symptoms.


Asunto(s)
Anticuerpos Antinucleares/sangre , Carcinoma de Células Escamosas/complicaciones , Neoplasias Pulmonares/complicaciones , Miositis/complicaciones , Anciano , Biomarcadores/sangre , Carcinoma de Células Escamosas/diagnóstico por imagen , Carcinoma de Células Escamosas/patología , Carcinoma de Células Escamosas/cirugía , Humanos , Neoplasias Pulmonares/diagnóstico por imagen , Neoplasias Pulmonares/patología , Neoplasias Pulmonares/cirugía , Masculino , Miositis/sangre , Miositis/diagnóstico , Miositis/inmunología , Neumonectomía , Tomografía de Emisión de Positrones , Tomografía Computarizada por Rayos X , Resultado del Tratamiento
2.
Osteoarthritis Cartilage ; 24(9): 1500-8, 2016 09.
Artículo en Inglés | MEDLINE | ID: mdl-27034093

RESUMEN

OBJECTIVE: An overview of the economic consequences - overall costs as well as cost breakdown (direct and indirect) - of hip and knee osteoarthritis (OA) worldwide. METHODS: A systematic literature search of EMBASE, MEDLINE, Scopus and Cochrane databases for articles was performed independently by two rheumatologists who used the same predefined eligible criteria. Papers without abstracts and in languages other than English or French were excluded. Extracted costs were converted to an annual cost and to 2013 euros (€) by using the Consumer Price Index of the relevant countries and the 2013 Purchasing Power Parities between these countries and the European Union average. RESULTS: A total of 45 abstracts were selected, and 32 articles were considered for the review. The studied populations were heterogeneous: administrative, hospital and national health survey data. Annual total costs per patient ranged from 0.7 to 12 k€, direct costs per patient from 0.5 to 10.9 k€ and indirect costs per patient from 0.2 to 12.3 k€. The weighted average annual costs per patient living with knee and hip OA were 11.1, 9.5 and 4.4 k€ for total, direct and indirect costs, respectively. CONCLUSIONS: This review highlights the heterogeneity of studies and lack of methodologic consensus to obtain reliable cost-of-illness estimates for lower-limb OA. However, costs induced by the disease seem substantial and deserve to be more extensively explored.


Asunto(s)
Osteoartritis de la Rodilla , Costo de Enfermedad , Encuestas Epidemiológicas , Humanos , Articulación de la Rodilla , Osteoartritis de la Cadera
3.
Ann Dermatol Venereol ; 139(5): 355-62, 2012 May.
Artículo en Francés | MEDLINE | ID: mdl-22578339

RESUMEN

BACKGROUND: Biological drugs have become a major treatment for moderate-to-severe forms of psoriasis. We sought to evaluate the characteristics of patients treated with biotherapies for psoriasis in daily practice in the dermatology and rheumatology departments of the University Hospital of Reims. PATIENTS AND METHODS: This retrospective study included all psoriasis patients treated with biological agents in the dermatology or rheumatology departments between March 2005 and June 2009. Data concerning the characteristics of psoriasis patients and treatments were collected using a standardized form. In June 2010, we evaluated therapeutic efficacy after at least 1 year of treatment with the first prescribed biotherapy. RESULTS: We note that 109 patients were included in the study (70 in dermatology and 39 in rheumatology). In dermatology, the mean age at diagnosis of psoriasis was 27 years. The sex ratio was 2.5. Of these patients, 26% were smokers, 19% were obese and 29% had dyslipidaemia. In most patients, psoriasis affected between 10% and 50% of body surface area. Thirty percent had associated psoriatic arthritis (confirmed by a rheumatologist in 17% of cases). The mean time from diagnosis to initial systemic treatment was 7 years, and 21 years to use of the first biotherapy. On average, patients received three systemic treatments before the introduction of biological drugs. In rheumatology, the mean age at diagnosis was 37 years. In 95% of patients, psoriasis affected less than 10% of the body surface area. The mean time from diagnosis to initial systemic treatment was 5 years, and 9 years to use of the first biotherapy; 41% of patients were referred to a dermatologist. There was no significant difference between the groups in terms of comorbidities except for dyslipidaemia, which was noted more frequently by dermatologists. DISCUSSION: This study shows little difference between patients treated in the dermatology and in the rheumatology departments in terms of psoriasis characteristics or comorbidities. However, patients in both groups exhibit more cardiovascular risk factors than the general population and 30% had psoriatic arthritis. These two points highlight the importance of the interaction between dermatologists and rheumatologists and the sentinel role of dermatologists in the management of comorbidities. In terms of efficacy, more than 70% of patients were satisfactorily controlled by biotherapy after 1 year of treatment. Therapeutic failures were more common in dermatology than in rheumatology.


Asunto(s)
Artritis Psoriásica/tratamiento farmacológico , Productos Biológicos/uso terapéutico , Psoriasis/tratamiento farmacológico , Adolescente , Adulto , Anciano , Niño , Preescolar , Dermatología , Femenino , Francia , Hospitales Universitarios , Humanos , Masculino , Persona de Mediana Edad , Pautas de la Práctica en Medicina , Estudios Retrospectivos , Reumatología , Adulto Joven
4.
Vaccine ; 33(46): 6152-5, 2015 Nov 17.
Artículo en Inglés | MEDLINE | ID: mdl-26458794

RESUMEN

Revaxis(®) is a vaccine against diphtheria, tetanus and poliomyelitis (dT-IPV). This vaccine should not be administered by the intradermal or intravenous route. Poor injection techniques and related consequences are rare. We report a case of bursitis associated with reactive glenohumeral effusion complicated by bone erosion occurring after injection of the dT-IPV vaccine. A 26 year old patient was admitted for painful left shoulder causing functional impairment. Control magnetic resonance imaging showed bone oedema on the upper outer part of the humeral head, with a slight cortical irregularity, indicating that the vaccine was injected in contact with the bone at this location, causing erosion. Outcome was favourable after intra-articular corticosteroids. Reports of articular or periarticular injury after vaccination are extremely rare, in view of the substantial number of vaccines administered every year. The potential complications of vaccination are well known to general practitioners but under-reported in the literature.


Asunto(s)
Resorción Ósea/inducido químicamente , Resorción Ósea/epidemiología , Bursitis/inducido químicamente , Bursitis/epidemiología , Vacuna contra Difteria y Tétanos/efectos adversos , Vacuna Antipolio de Virus Inactivados/efectos adversos , Adulto , Vacuna contra Difteria y Tétanos/administración & dosificación , Femenino , Humanos , Húmero/patología , Vacuna Antipolio de Virus Inactivados/administración & dosificación , Articulación del Hombro/patología , Vacunas Combinadas/administración & dosificación , Vacunas Combinadas/efectos adversos
5.
Pathol Res Pract ; 190(7): 690-6, 1994 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-7808967

RESUMEN

Rheumatoid hyperplastic synovial lining cells and sublining fibroblasts are known to produce, in vivo and in vitro, matrix metallo-proteinases which degrade extracellular matrix components of joints. We have studied by immunohistochemistry and in situ hybridization the presence of matrix metallo-proteinase stromelysin 3 and its potential inhibitors TIMP-1 and TIMP-2 in 5 cases of normal synovia, 5 cases of chronic synovitis and 12 cases of rheumatoid arthritis. Few hyperplastic synoviocytes and some sparse fibroblasts have been found to produce stromelysin 3 in all rheumatoid arthritis and 2 chronic synovitis. Stromelysin 3 seems to have a limited role in the destructive process of extracellular matrix. TIMP-1 and TIMP-2 were largely expressed principally in hyperplastic synoviocytes and in endothelial cells of all rheumatoid synovitis and 2 chronic synovitis. These findings plead for a balance between matrix metallo-proteinases and their inhibitors in these inflammatory lesions.


Asunto(s)
Artritis Reumatoide/metabolismo , Glicoproteínas/biosíntesis , Metaloendopeptidasas/biosíntesis , Biosíntesis de Proteínas , Northern Blotting , Humanos , Técnicas para Inmunoenzimas , Hibridación in Situ , Metaloproteinasa 11 de la Matriz , Metaloendopeptidasas/antagonistas & inhibidores , Membrana Sinovial/química , Sinovitis/metabolismo , Inhibidor Tisular de Metaloproteinasa-2 , Inhibidores Tisulares de Metaloproteinasas
6.
Clin Nucl Med ; 15(12): 908-10, 1990 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-2276234

RESUMEN

This study is based on 20 patients who underwent bone scanning before and after chemonucleolysis (CN) for a herniated lumbar disk. It shows that chymopapain, the proteolytic enzyme used for CN, does not induce early or late bone lesions of the adjacent vertebral plates. Abnormal uptake by one of the vertebral plates indicates a "chemical discitis." The pattern observed on the bone scan is different from the one presented by patients with bacterial spondylitis.


Asunto(s)
Quimopapaína/uso terapéutico , Discitis/diagnóstico por imagen , Quimiólisis del Disco Intervertebral , Desplazamiento del Disco Intervertebral/diagnóstico por imagen , Vértebras Lumbares/diagnóstico por imagen , Quimopapaína/efectos adversos , Discitis/etiología , Humanos , Desplazamiento del Disco Intervertebral/terapia , Cintigrafía
7.
Rev Med Interne ; 13(4): 273-7, 1992.
Artículo en Francés | MEDLINE | ID: mdl-1287767

RESUMEN

An improved knowledge of the initial prognostic factors of multiple myeloma and regular monitoring of the disease should result in the choice of the most effective treatment. The conventional prognostic factors have been divided into three stages by Durie and Salmon. These stages are based on the proportion and type of the monoclonal component, on haemoglobin, calcium and creatinine blood levels and on the extent of bone lesions. However, this widely used classification has certain disadvantages: the size of the tumoral mass is evaluated mainly from the proportion of monoclonal gammopathy, the bone lesions are difficult to determine and the kinetics of cell proliferation are not taken into account. Parameters with high prognostic value have recently been demonstrated; they include beta 2-microglobulin, LDH, interleukin-6, C-reactive protein, serum albumin and kinetic of cell proliferation. When associated, these data allow to establish prognostic staying that are at least as relevant as those of the Durie-Salmon's classification. Monitoring of patients with multiple myeloma by means of a time-related curve of either the tumoral mass or the amount of monoclonal gammopathy leads to the best possible treatment.


Asunto(s)
Mieloma Múltiple/clasificación , Humanos , Monitoreo Fisiológico , Mieloma Múltiple/sangre , Mieloma Múltiple/diagnóstico por imagen , Pronóstico , Radiografía
8.
Rev Med Interne ; 18(4): 286-91, 1997.
Artículo en Francés | MEDLINE | ID: mdl-9161555

RESUMEN

PURPOSE: To establish the possible connection between visceral, arthro-cutaneous and biological spreading of systemic lupus (SL) and hours of sunlight. MATERIAL AND METHODS: Retrospective study of 66 SL patients, consisting of 52 visceral and 14 arthro-cutaneous cases taking into account the chronological pattern of each new aggravation, based on 480 clinical records. RESULTS: Increased frequency in visceral aggravation was observed in the post-summer period (August-January) (n = 57), as compared with the pre-summer period (February-July) (n = 25) (RR = 1.75, P = 0.006). This post-summer visceral aggravation was correlated with cutaneous affection (RR = 4.18) and absence of previous corticotherapy (RR = 3.97). Visceral and arthro-cutaneous aggravations taken together revealed a more disturbed immune balance pattern in the post-summer period (anti-dsDNA: 30 versus 25.1 IU/L [P = 0.07]; C3: 0.83 vs 0.921 IU/L [P = 0.05]; C4: 0.146 vs 0.183 [P = 0.05]), providing evidence of greater severity. Moderate thrombopenia (50-120 10(9)/L) accompanying visceral SL with antiphospholipids (n = 33) was more frequent during the post-summer period, even in the absence of aggravation (P = 0.03). The quarterly distribution of visceral aggravations was correlated with average hours of sunlight in the preceding quarter (P = 0.01). CONCLUSION: There is a post-summer increase in the frequency and severity of visceral SL spreading correlated to cutaneous exacerbation and sunlight.


Asunto(s)
Lupus Eritematoso Sistémico/fisiopatología , Estaciones del Año , Adulto , Femenino , Humanos , Lupus Eritematoso Sistémico/inmunología , Lupus Eritematoso Sistémico/prevención & control , Masculino , Trastornos por Fotosensibilidad/prevención & control , Estudios Retrospectivos , Factores de Riesgo , Luz Solar
9.
Rev Med Interne ; 5(4): 298-302, 1984 Nov.
Artículo en Francés | MEDLINE | ID: mdl-6097979

RESUMEN

We report a new case of cutaneous mucormycosis in a diabetic woman. The major favouring circumstances are found in this patient: ketoacidosis diabetes, use of bandages, local corticosteroid applications, renal insufficiency. The diagnosis, rarely made on the clinical aspect, is based on the histological and mycological data. A trial of treatment by ketoconazole has been carried out, but without success. The usual treatment by intravenous amphotericine B has been successful.


Asunto(s)
Dermatomicosis/etiología , Diabetes Mellitus Tipo 1/complicaciones , Mucormicosis/etiología , Anfotericina B/uso terapéutico , Vendajes/efectos adversos , Moldes Quirúrgicos/efectos adversos , Dermatomicosis/tratamiento farmacológico , Femenino , Humanos , Cetoconazol/uso terapéutico , Persona de Mediana Edad , Mucormicosis/tratamiento farmacológico
10.
Rev Med Interne ; 17(4): 291-9, 1996.
Artículo en Francés | MEDLINE | ID: mdl-8761792

RESUMEN

Clinical, roentgenologic, functional and broncho-alveolar lavage features of lung involvement in primary Sjögren's syndrome were assessed in a retrospective study of 35 cases. Diffuse interstitial patterns on chest radiography were present in six patients and alveolar patterns were suggestive of lymphoid interstitial pneumonitis or pseudolymphoma in two. Acute and febrile onset mimicked infectious pneumonitis in three patients when dyspnea was the most common clinical feature in others. Patients with primary Sjögren's syndrome and pulmonary disease were older (65 vs 56 years) (P = 0.025), have more frequently extra-glandular manifestations (P = 0.03), keratoconjunctivis sicca (P = 0.018) and biological perturbations (hypergammaglobulinemia (P = 0.03), antinuclear antibodies (P = 0.01) than those without lung involvement. Low diffusion capacity was present in seven patients associated twice to small airways obstruction. Bronchoalveolar lavage revealed in all cases an increased total cells count (mean: 6.96 10(5)/mm3) and a lymphocytic alveolitis (range: 11 to 66%; mean: 38%) associated with an elevated percentage of alveolar neutrophils in four patients. A low CD4/CD8 ratio was related to a pejorative issue. Treatment consisted in corticotherapy combined with oral cyclophosphamide in case of pseudolymphoma.


Asunto(s)
Enfermedades Pulmonares/etiología , Síndrome de Sjögren/complicaciones , Anciano , Bronquios/patología , Líquido del Lavado Bronquioalveolar/citología , Ciclofosfamida/uso terapéutico , Diagnóstico Diferencial , Quimioterapia Combinada , Femenino , Glucocorticoides/uso terapéutico , Humanos , Inmunosupresores/uso terapéutico , Enfermedades Pulmonares/diagnóstico , Enfermedades Pulmonares/terapia , Enfermedades Pulmonares Intersticiales/diagnóstico , Enfermedades Pulmonares Intersticiales/etiología , Enfermedades Pulmonares Intersticiales/terapia , Linfoma/diagnóstico , Linfoma/terapia , Masculino , Persona de Mediana Edad , Prednisona/uso terapéutico , Estudios Retrospectivos , Síndrome de Sjögren/diagnóstico , Síndrome de Sjögren/terapia
11.
Rev Med Interne ; 14(8): 780-3, 1993.
Artículo en Francés | MEDLINE | ID: mdl-8191090

RESUMEN

Schnitzler's syndrome has been described in 1972. It associates a chronic urticaria with leukocytoclastic vasculitis, a macroglobulinemia, bone pains, hyperostosis. In the twenty three cases reported, the evolution is benign but three patients including the princeps case developed a Waldenström's disease or a lymphoplasmocytic lymphoma. We present the case of one patient, aged 65, with Schnitzler's syndrome, who, after 6 years evolution, presents a IgM myeloma. Schnitzler's syndrome appeared as a pre-hemopathic state which has to be taken care of regularly and for a long time.


Asunto(s)
Inmunoglobulina M , Mieloma Múltiple/etiología , Urticaria/complicaciones , Macroglobulinemia de Waldenström/complicaciones , Corticoesteroides/uso terapéutico , Anciano , Clorambucilo/uso terapéutico , Enfermedad Crónica , Humanos , Masculino , Mieloma Múltiple/tratamiento farmacológico , Síndrome , Factores de Tiempo , Urticaria/tratamiento farmacológico , Urticaria/fisiopatología , Macroglobulinemia de Waldenström/tratamiento farmacológico , Macroglobulinemia de Waldenström/fisiopatología
12.
Rev Med Interne ; 34(1): 42-6, 2013 Jan.
Artículo en Francés | MEDLINE | ID: mdl-23036779

RESUMEN

INTRODUCTION: The prevalence of vertebral sarcoidosis is highly variable (1 to 36% of reported case series). Because of limited clinical expression, its frequency is probably underestimated. Its proper management is not clearly defined. CASE REPORT: A 42-year-old woman who had a past medical history of cutaneous and pulmonary sarcoidosis presented with low back pain that was refractory to usual medical treatment. A diagnosis of vertebral localisation of sarcoidosis was considered on the history of proven sarcoidosis, radiological features, and the absence of evidence of an alternative diagnosis. In the absence of other clinical or biological evidence of active sarcoidosis, a simple follow-up was planned. MRI control at 1 year showed the resolution of vertebral sarcoidosis lesions. CONCLUSION: Spontaneous regression is a possible outcome of vertebral sarcoidosis. Initiation of a specific treatment should be discussed in the absence of other visceral involvement.


Asunto(s)
Vértebras Lumbares/patología , Sarcoidosis/diagnóstico , Enfermedades de la Columna Vertebral/diagnóstico , Adulto , Femenino , Estudios de Seguimiento , Humanos , Dolor de la Región Lumbar/diagnóstico , Remisión Espontánea , Sarcoidosis Pulmonar/diagnóstico , Enfermedades de la Piel/diagnóstico , Espera Vigilante
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA